Market Overview:
The global CIS insulin market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising awareness about diabetes and its treatment, and technological advancements in the field of insulin delivery devices. Based on type, the global CIS insulin market is segmented into long-acting analogs, rapid acting analogs, premixed analogs, intermediate insulins, and short acting insulins. Of these segments, the long-acting analog segment is expected to witness highest growth during the forecast period owing to their longer duration of action as compared to other types of insulin available in the market. Based on application type, CIS Insulin Market is classified as Type I Diabetes Mellitus (T1DM) and Other Diabetes Mellitus (ODM), which further includes gestational diabetes mellitus (GDM), secondary diabetes mellitus etc., with Type I Diabetes Mellitus accounting for majority share in terms of revenue generated by application type during 2018-2030.
Product Definition:
CIS insulin is a short-acting insulin that is used to treat diabetes mellitus. It is important because it helps to regulate blood sugar levels.
Long-Acting Analog:
Analogs are man-made drugs that are similar to human insulin but have a longer duration of action. They work by binding to the same site in the body as human insulin and helping it to act for a longer period, usually 4 - 12 hours. Analogs can be used with other anti-diabetics such as metformin and lifestyle changes can reduce the risk of complications associated with diabetes.
Rapid Acting Analog:
Rapid acting analogs are a class of drug that works by increasing the rate at which insulin is absorbed into the blood cells. The rapid absorption property of these drugs helps in treating low blood sugar (hypoglycemia), which occurs when there is little or no food in the stomach.
Application Insights:
The other diabetes segment held the largest market share of over 60% in 2017. Other diabetes includes both type II and type I diabetes. Type II is further categorized into two sub-groups, namely, adult-onset and youth-onset. The adult-onset category comprises those patients who had been diagnosed with the disease at a relatively older age (above 40 years). Type I is considered to be a disease of insulin production or secretion by the body due to an absence or deficiency in its ability to produce sufficient insulin for proper functioning of internal organs such as kidneys, liver and brain. This condition is prevalent among children and young adults (below 30 years).
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its dominance over the forecast period as well due to increasing prevalence of type I and type II diabetes, rising awareness about insulin therapy, availability of highly advanced medical facilities for diagnosis and treatment, supportive government initiatives & reimbursement policies, presence of major market players and many other factors.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to improving healthcare infrastructure & facilities for treating diabetes; growing population with a high risk factor; increasing disposable income especially in emerging countries such as China & India; rising awareness among people regarding available therapies such as long-acting insulin analogs and rapid acting analogs along with their advantages/disadvantages compared to traditional insulins are some other factors that can be attributed towards this growth.
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is primarily attributed to the changing lifestyle and dietary habits of people across the world. According to a study by the International Diabetes Federation, there were 415 million people living with diabetes in 2015, and this number is expected to reach 642 million by 2030. This will create a large pool of patients who will require treatment with insulin, thereby driving the growth of CIS Insulin market.
- Rising awareness about diabetes and its complications: There has been a significant increase in awareness about diabetes and its complications in recent years due to various campaigns launched by healthcare organizations as well as governments across the world. This has led more people to seek diagnosis and treatment for diabetes, thereby driving demand for CIS Insulin products.
Scope Of The Report
Report Attributes
Report Details
Report Title
CIS Insulin Market Research Report
By Type
Long-Acting Analog, Rapid Acting Analog, Premixed Analog, Intermediate Insulin, Short Acting Insulin, Premixed Insulin
By Application
Type I and Other Diabetes, Type II Diabetes
By Companies
Eli Lilly, Novo Nordisk, Takeda Pharmaceuticals, Sanofi Aventis, Nanjing Xinbai Pharmaceutical, Oramed Pharmaceuticals, Merck, Boehringer Ingelheim, Biocon
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
195
Number of Tables & Figures
137
Customization Available
Yes, the report can be customized as per your need.
Global CIS Insulin Market Report Segments:
The global CIS Insulin market is segmented on the basis of:
Types
Long-Acting Analog, Rapid Acting Analog, Premixed Analog, Intermediate Insulin, Short Acting Insulin, Premixed Insulin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Type I and Other Diabetes, Type II Diabetes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- Novo Nordisk
- Takeda Pharmaceuticals
- Sanofi Aventis
- Nanjing Xinbai Pharmaceutical
- Oramed Pharmaceuticals
- Merck
- Boehringer Ingelheim
- Biocon
Highlights of The CIS Insulin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Long-Acting Analog
- Rapid Acting Analog
- Premixed Analog
- Intermediate Insulin
- Short Acting Insulin
- Premixed Insulin
- By Application:
- Type I and Other Diabetes
- Type II Diabetes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CIS Insulin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CIS insulin is a type of insulin that is used to treat diabetes. It works by helping the body to control blood sugar levels.
Some of the key players operating in the cis insulin market are Eli Lilly, Novo Nordisk, Takeda Pharmaceuticals, Sanofi Aventis, Nanjing Xinbai Pharmaceutical, Oramed Pharmaceuticals, Merck, Boehringer Ingelheim, Biocon.
The cis insulin market is expected to grow at a compound annual growth rate of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 CIS Insulin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 CIS Insulin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 CIS Insulin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the CIS Insulin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global CIS Insulin Market Size & Forecast, 2020-2028
4.5.1 CIS Insulin Market Size and Y-o-Y Growth
4.5.2 CIS Insulin Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Long-Acting Analog
5.2.2 Rapid Acting Analog
5.2.3 Premixed Analog
5.2.4 Intermediate Insulin
5.2.5 Short Acting Insulin
5.2.6 Premixed Insulin
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Type I and Other Diabetes
6.2.2 Type II Diabetes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global CIS Insulin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 CIS Insulin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Long-Acting Analog
9.6.2 Rapid Acting Analog
9.6.3 Premixed Analog
9.6.4 Intermediate Insulin
9.6.5 Short Acting Insulin
9.6.6 Premixed Insulin
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Type I and Other Diabetes
9.10.2 Type II Diabetes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Long-Acting Analog
10.6.2 Rapid Acting Analog
10.6.3 Premixed Analog
10.6.4 Intermediate Insulin
10.6.5 Short Acting Insulin
10.6.6 Premixed Insulin
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Type I and Other Diabetes
10.10.2 Type II Diabetes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Long-Acting Analog
11.6.2 Rapid Acting Analog
11.6.3 Premixed Analog
11.6.4 Intermediate Insulin
11.6.5 Short Acting Insulin
11.6.6 Premixed Insulin
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Type I and Other Diabetes
11.10.2 Type II Diabetes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Long-Acting Analog
12.6.2 Rapid Acting Analog
12.6.3 Premixed Analog
12.6.4 Intermediate Insulin
12.6.5 Short Acting Insulin
12.6.6 Premixed Insulin
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Type I and Other Diabetes
12.10.2 Type II Diabetes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Long-Acting Analog
13.6.2 Rapid Acting Analog
13.6.3 Premixed Analog
13.6.4 Intermediate Insulin
13.6.5 Short Acting Insulin
13.6.6 Premixed Insulin
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Type I and Other Diabetes
13.10.2 Type II Diabetes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 CIS Insulin Market: Competitive Dashboard
14.2 Global CIS Insulin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly
14.3.2 Novo Nordisk
14.3.3 Takeda Pharmaceuticals
14.3.4 Sanofi Aventis
14.3.5 Nanjing Xinbai Pharmaceutical
14.3.6 Oramed Pharmaceuticals
14.3.7 Merck
14.3.8 Boehringer Ingelheim
14.3.9 Biocon
